Dextenza effectively controls inflammation after iStent or Hydrus insertion during cataract surgery
Dextenza effectively controls inflammation after iStent or Hydrus insertion during cataract surgery suggests a recent study published in the Journal of Glaucoma
Using an intracanalicular dexamethasone insert or topical prednisolone following iStent and Hydrus surgery provided similar short-term control of postoperative inflammation.
The purpose of this study was to compare postoperative inflammation in patients who received an intracanalicular dexamethasone insert or topical prednisolone after iStent or Hydrus insertion during cataract surgery.
Patients receiving a dexamethasone insert after iStent or Hydrus insertion were included and compared with age-matched controls who received topical prednisolone. Preoperative data were recorded. Postoperative inflammatory cell and the proportion of patients with zero anterior chamber cells was recorded at month 1. Postoperative intraocular pressure (IOP) and rate of cystoid macular edema were recorded at months 1 and 3.
Results:
- Forty eyes receiving topical prednisolone were compared with 35 eyes receiving a dexamethasone insert after iStent or Hydrus insertion.
- The mean postoperative inflammatory cell for the topical group at month 1 was 0.2±0.3, and the dexamethasone group, 0.3±0.5 (P=0.816). Overall, 70% of patients in the topical group had zero anterior chamber cell at postoperative month 1 compared with 75.8% in the dexamethasone group (P=0.583).
- The mean preoperative IOP for the topical group was 18.8±5.5 and the dexamethasone group was 17.1±4.1 (P=0.064).
- Mean postoperative IOP for the topical group at months 1 and 3 was 17.6±6.4 and 15.1±3.1, respectively and the dexamethasone group, 17.5±4.8 and 15.0±3.4, respectively (P=0.772 and 0.884).
- One patient developed cystoid macular edema in each group.
Thus, there was no statistically significant difference in the proportion of patients who had zero anterior chamber cell at postoperative month 1 between groups receiving intracanalicular dexamethasone insert or topical prednisolone.
Reference:
Jackson, Kevin J. MD*; Akrobetu, Dennis BS†; Guduru, Abhilash MD*; Herndon, Leon W. MD*. Intracanalicular Dexamethasone Insert or Topical Prednisolone Following iStent and Hydrus Surgery for Glaucoma. Journal of Glaucoma: August 2022 - Volume 31 - Issue 8 - p 694-699 doi: 10.1097/IJG.0000000000002037
Keywords:
Dextenza, effectively, controls, inflammation, iStent, or Hydrus, insertion, cataract surgery, Jackson, Kevin J, Akrobetu, Dennis; Guduru, Abhilash; Herndon, Leon W, Journal of Glaucoma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.